China quietly became biotech’s back-office, from molecule synthesis and clinical trials to novel drug licensing. Now the ...

China's pharmaceutical industry surges on ageing demand and global expansion, with revenue forecast to top US$2.1 trillion by ...

Global institutional investors have built up sizeable positions in firms including Innovent, 3SBio, WuXi Biologics, Jiangsu ...

Breeders did not increase their populations during an investment downturn in 2023, contributing to a supply squeeze.

During the 2026 J.P. Morgan Healthcare Conference (JPM), the 2026 China FIC Innovation & Collaboration Summit was successfully held in San Francisco, the United States. Organized by the ZFIC Alliance, ...

In the past three weeks, a flurry of licensing deals with Chinese biotechs were announced featuring AbbVie, AstraZeneca, ...

Smiley also details how Zai Lab blends China’s development speed capabilities with global clinical and regulatory standards, ...

Four recent deals fueled more angst about China’s biotech progress, while Pfizer, Bristol Myers and Sarepta all worked to ...

In the past five years, China has leaped from fast follower to global pioneer in drug discovery and development. We believe that Chinese companies have established large competitive advantages in ...

Ellipses Pharma Limited (“Ellipses”), a clinical-stage oncology drug development company with a pipeline of innovative ...

International pharmaceutical leaders and investors gathered in San Francisco on Sunday to explore partnership opportunities ...